Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
002030.SZ
HOLDREMOVEDaan Gene Co., Ltd. · Healthcare · China · $1.5B · Avg Vol: $68M/d
Daan Gene is an in-vitro diagnostics company. Following the collapse of pandemic-era PCR testing demand, the company faces severe overcapacity, price wars, and a lack of high-margin recurring revenue streams.
COMPANY DESCRIPTION
Daan Gene Co., Ltd. develops and manufactures in vitro diagnostic (IVD) reagents and instruments, specializing in PCR-based molecular diagnostics. The company is a dominant player in China's molecular diagnostics market, backed by strong academic ties and clinical validation. It operates as a leading biotechnology firm with a highly integrated R&D, manufacturing, and clinical testing network.
FINANCIAL SUMMARY
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 1.8B | 175M | 126M | 112M | -60.2% |
| EPS | 0.57 | 0.01 | -0.10 | -0.08 | -98.2% |
| Shares | 1.4B | 1.4B | 1.4B | 1.4B | 0.0% |
| Debt | 33M | 54M | 25M | 17M | -20.1% |
| Equity | 1.7B | 1.3B | 1.2B | 1.1B | -14.2% |
| Op CF | 614M | 115M | 44M | 47M | -57.5% |
| Inv CF | -290M | -9M | -32M | -94M | — |
| Fin CF | -265M | -343M | -30M | -7M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002030.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 002030.SZ | Daan Gene Co., Ltd.(you) | $1.5B | 57 | HOLD |
| 688513.SS | Chengdu Easton Biopharmaceuticals Co., Ltd. | $1.4B | 55 | HOLD |
| 605116.SS | Aurisco Pharmaceutical Co.,Ltd. | $1.2B | 56 | HOLD |
| 688253.SS | Innovita Biological Technology Co., Ltd. | $1.1B | 58 | HOLD |
| 002287.SZ | Tibet Cheezheng Tibetan Medicine Co., Ltd. | $1.8B | 60 | HOLD |
| 688202.SS | Shanghai Medicilon Inc. | $1.2B | 53 | HOLD |
| 000990.SZ | Chengzhi Co., Ltd. | $1.7B | 63 | HOLD |
| 301207.SZ | Hualan Biological Vaccine Inc. | $1.6B | 47 | HOLD |
| 688105.SS | Nanjing Vazyme Biotech Co., Ltd | $1.1B | 63 | HOLD |
| 688222.SS | HitGen Inc. | $1.8B | 47 | HOLD |
Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.1%